Safety Alerts & Recalls

Search all Safety Alerts & Recalls

Latest Alerts

FDA Announces Ongoing Safety Review of Angiotensin Receptor Blockers (ARBs) for Cancer Risk
The U.S. Food and Drug Administration (FDA) is conducting a review of the class of medications known as angiotensin receptor blockers (ARBs) after a recently published study suggested they may be associated with a small increased risk of cancer. ARBs are used to treat high blood pressure, heart failure, and to reduce risk of heart disease. The FDA has not concluded that ARBs increase the risk of cancer. The Agency is reviewing information related to this safety concern and will update the public when additional information is available. Seven different ARBs are currently available in the U.S: candesartan (Atacand), eprosartan (Teveten), irbesartan (Avapro), losartan (Cozaar), olmesartan (Benicar), telmisartan (Micardis), and valsartan (Diovan). ARBs are also sold in combination with other blood pressure medicines under the brand names Atacand HCT, Teveten HCT, Avalide, Hyzaar (and its generic name losartan and hydrochlorothiazide), Azor, Benicar HCT, Twynysta, Micardis HCT, Valturna, Exforge, Exforge HCT, and Diovan HCT. For more information, please visit: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm218845.htm
Learn More

FDA Completes Safety Review: Angiotensin Receptor Blockers (ARBs) for High Blood Pressure Do Not Increase Risk of Cancer
Today, the U.S. Food and Drug Administration (FDA) announced it has completed a review of the potential risk of cancer associated with the class of blood pressure medications known as angiotensin receptor blockers (ARBs). This review was first described in a July 2010 safety review announcement. The FDA review and analysis of all currently available data regarding this potential safety signal has determined that treatment with an ARB medication does not increase the risk of cancer. Seven different ARBs are currently available in the U.S: candesartan (Atacand), eprosartan (Teveten), irbesartan (Avapro), losartan (Cozaar), olmesartan (Benicar), telmisartan (Micardis), and valsartan (Diovan). ARBs are also sold in combination with other blood pressure medicines under the brand names Atacand HCT, Teveten HCT, Avalide, Hyzaar (and its generic name losartan and hydrochlorothiazide), Azor, Benicar HCT, Twynysta, Micardis HCT, Valturna, Exforge, Exforge HCT, and Diovan HCT. For more information, please visit: http://www.fda.gov/Drugs/DrugSafety/ucm257516.htm
Learn More

Date Published Title Drug Source
2010-07-16 FDA Announces Ongoing Safety Review of Angiotensin Receptor Blockers (ARBs) for Cancer Risk Telmisartan FDA
2011-06-02 FDA Completes Safety Review: Angiotensin Receptor Blockers (ARBs) for High Blood Pressure Do Not Increase Risk of Cancer Telmisartan FDA
2009-11-12 Recall on a Single Lot of Temodar Capsules 5 mg Temozolomide FDA
2012-05-01 Schering-Plough Products Recalls Single Lot of Temodar (temozolomide capsules), 5 mg Temozolomide FDA
2008-09-18 FDA Stops Imports of Ranbaxy Products Terazosin FDA
2010-03-16 Cadista Has Completed Its Recall Of Terazosin 5 mg Capsules Terazosin FDA
2011-02-18 Terbutaline: Change To the Prescribing Information - Boxed Warning Against Use for Treatment of Preterm Labor Terbutaline FDA
2008-07-03 New Consumer Guide for Patients Teriparatide MediGuard CRT
2011-03-18 Lilly Informs Customers of Important Information About Alcohol Prep Pads in Forteo Starter Kits Teriparatide Manufacturer
2009-03-09 Risk of Burns during MRI Scans from Transdermal Drug Patches with Metallic Backings Testosterone FDA
2009-05-07 Boxed Warning Added to Testosterone Gel Products (Androgel, Testim) Testosterone FDA
2009-01-23 Safety Alert on Incorrect Use of Skin Numbing Products Tetracaine FDA
2011-11-09 Manufacturing Delays May Affect Availability of Antibiotic Tetracycline Tetracycline FDA
2012-02-02 Teva Pharmaceuticals USA, Inc Recalls Select Lots of Tetracycline Capsules 500 mg Tetracycline FDA
2012-05-15 Teva Pharmaceuticals USA, Inc Recalls Several Lots of Tetracycline HCl Capsules USP, 250 mg and 500 mg Tetracycline FDA
2012-10-25 Keep Eye Drops and Nasal Sprays Out of Kids' Reach Tetrahydrozoline FDA
2008-06-17 New Boxed Warning on Older Class of Antipsychotic Drugs Thioridazine FDA
2009-01-15 Antipsychotics Linked to Heart Risks Thioridazine MediGuard CRT
2009-06-08 Antipsychotics Linked With Sudden Cardiac Death Thioridazine MediGuard CRT
2008-06-17 New Boxed Warning on Older Class of Antipsychotic Drugs Thiothixene FDA
Back to Consumer Med Safety